DOI QR코드

DOI QR Code

Differences in the Prognostic Significance of the SUVmax between Patients with Resected Pulmonary Adenocarcinoma and Squamous Cell Carcinoma

  • Motono, Nozomu (Department of Thoracic Surgery, Kanazawa Medical University) ;
  • Ueno, Masakatsu (Department of Thoracic Surgery, Kanazawa Medical University) ;
  • Tanaka, Makoto (Department of Thoracic Surgery, Kanazawa Medical University) ;
  • Machida, Yuichiro (Department of Thoracic Surgery, Kanazawa Medical University) ;
  • Usuda, Katsuo (Department of Thoracic Surgery, Kanazawa Medical University) ;
  • Sakuma, Tsutomu (Department of Thoracic Surgery, Kanazawa Medical University) ;
  • Sagawa, Motoyasu (Department of Thoracic Surgery, Kanazawa Medical University)
  • Published : 2015.01.06

Abstract

Background: The purpose of this study was to determine the prognostic significance of the maximum standardized uptake value (SUVmax) on F-18-fluorodeoxyglucose (FDG)-positron emission tomography (PET) in patients undergoing surgical treatment for non-small cell lung cancer. Materials and Methods: Seventy-eight consecutive patients (58 with adenocarcinomas, 20 with squamous cell carcinomas) treated with potentially curative surgery were retrospectively reviewed. Results: The SUVmax was significantly higher in the patients with recurrent than with non-recurrent adenocarcinoma (p<0.01). However, among the patients with squamous cell carcinoma, there were no differences with or without recurrence (p=0.69). Multivariate analysis indicated that the SUVmax of adenocarcinoma lesions was a significant predictor of disease-free survival (p=0.04). In addition, an SUVmax of 6.19, the cut-off point based on ROC curve analysis of the patients with pathological IB or more advanced stage adenocarcinomas, was found to be a significant predictor of disease-free survival (p<0.01). Conclusions: SUVmax is a useful predictor of disease-free survival in patients with resected adenocarcinoma, but not squamous cell carcinoma. Patients with adenocarcinoma exhibiting an SUVmax above 6.19 are candidates for more intensive adjuvant therapy.

Keywords

Non-small cell lung cancer;histologic type;PET;maximum standardized uptake value;prognosis

References

  1. Alberts W (2007). Follow up and surveillance of the patient with lung cancer: What do you do after surgery? Respirology, 12, 16-21. https://doi.org/10.1111/j.1440-1843.2006.00956.x
  2. Al-Jahdali H, Khan AN, Loutfi S, Al-Harbi AS (2012). Guidelines for the role of FDG-PET/CT in lung cancer management. J Infect Public Health, 5, 35-40. https://doi.org/10.1016/j.jiph.2011.10.007
  3. Al-Sarraf N, Gately K, Lucey J, et al (2008). Clinical implication and prognostic significance of standardized uptake value of primary non-small cell lung cancer on positron emission tomography:analysis of 176 cases. Eur J Cardiothorac Surg, 34, 892-7. https://doi.org/10.1016/j.ejcts.2008.07.023
  4. de Geus-Oei LF, van der Heijden H, Corstens F, Oyen W (2007). Predictive and prognostic value of FDG-PET in nonsmallcell lung cancer. Cancer, 110, 1654-64. https://doi.org/10.1002/cncr.22979
  5. Ding XP, Zhang J, Li BS, et al (2012). Feasibility of shrinking field radiation therapy through 18F-FDG PET/CT after 40 Gy for stage III non-small cell lung cancers. Asian Pac J Cancer Prev, 13, 319-23. https://doi.org/10.7314/APJCP.2012.13.1.319
  6. Hasbek Z, Yucel B, Salk I, et al (2014). Potential impact of atelectasis and primary tumor glycolysis on F-18 FDG PET/ CT on survival in lung cancer patients. Asian Pac J Cancer Prev, 15, 4085-9. https://doi.org/10.7314/APJCP.2014.15.9.4085
  7. Hicks RJ, Kaiff V, MacManus MP, et al (2001). The utility of 18F-FDG PET for suspected recurrence non-small cell lung cancer after potentially curative therapy: Impact on management and prognostic stratification. J Nucl Med, 42, 1605-13.
  8. Higashi K, Ueda Y, Arisaka Y, et al (2002). 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med, 43, 39-45.
  9. Higuchi M, Hasegawa T, Osugi J, Suzuki H, Gotoh M (2014). Prognostic impact of FDG-PET in surgically treated pathological stage I lung adenocarcinoma. Ann Thorac Cardiovasc Surg, 20, 185-91. https://doi.org/10.5761/atcs.oa.12.02219
  10. Hoekstra C, Stroobants S, Smit E, et al (2005). Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-d-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol, 23, 8362-70. https://doi.org/10.1200/JCO.2005.01.1189
  11. Kaya AO, Coskun Y, Unlu M, et al (2008). Whole body 18F-FDG PET/CT imaging in the detection of primary tumors in patients with a metastatic carcinoma of unknown origin. Asian Pac J Cancer Prev, 9, 683-6.
  12. Liu NB, Zhu L, Li MH, et al (2013). Diagnostic value of 18F-FDG PET/CT in comparison to bone scintigraphy, CT and 18F-FDG PET for the detection of bone metastasis. Asian Pac J Cancer Prev, 14, 3647-52. https://doi.org/10.7314/APJCP.2013.14.6.3647
  13. Mac Manus MP, Hicks RJ, Matthews JP, et al (2003). Positron emission tomography is superior to computed tomography scaning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol, 21, 1285-92. https://doi.org/10.1200/JCO.2003.07.054
  14. Martini N, Bains M, Burt M, et al (1995). Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg, 109, 120-9. https://doi.org/10.1016/S0022-5223(95)70427-2
  15. Mutlu H, Buyukcelik A, Erden A, et al (2013). Staging with PET-CT in patients with locally advanced non small cell lung cancer is superior to conventional staging methods in terms of survival. Asian Pac J Cancer Prev, 14, 3743-6. https://doi.org/10.7314/APJCP.2013.14.6.3743
  16. Patz EF Jr, Connolly J, Herndon J (2000). Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer. AJR, 174, 769-74. https://doi.org/10.2214/ajr.174.3.1740769
  17. Sasaki R, Komaki R, Macapinlac H, et al (2005). [18F] Fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol, 23, 1136-43. https://doi.org/10.1200/JCO.2005.06.129
  18. Shiono S, Abiko M, Okazaki T, et al (2011) Positron emission tomography for predicting recurrence in stage I lung adenocarcinoma: standardized uptake value corrected by mean liver standardized uptake value. Eur J Cardiothorac Surg, 40, 1165-9.
  19. Sugimura H, Nichols F, Yang P, et al (2007). Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection. Ann Thorac Surg, 83, 409-18. https://doi.org/10.1016/j.athoracsur.2006.08.046
  20. Vansteekiste JF, Stroobants SG, Dupont PJ, et al (1999). Prognostic importance of the standardized uptake value on 18F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer. An analysis of 125 cases. J Clin Oncol, 17, 3201-6.
  21. Walsh G, O'Connor M, Willis K, et al (1995). Is follow-up of lung cancer patients after resection medically indicated and cost-effective? Ann Thorac Surg, 60, 1563-72. https://doi.org/10.1016/0003-4975(95)00893-4
  22. Zhu SH, Zhang Y, Yu YH, et al (2013). FDG PET-CT in nonsmall cell lung cancer: relationship between primary tumor FDG uptake and extensional or metastatic potential. Asian Pac J Cancer Prev, 14, 2925-9. https://doi.org/10.7314/APJCP.2013.14.5.2925